Exact Sciences, a molecular diagnostics company, completed the acquisition of Base Genomics, a provider of DNA methylation technology, from Oxford Sciences Innovation, an early-stage venture capital firm, for $410m. “Our focus at OSI is to ensure Oxford’s world leading science moves out of the laboratory and onto the global stage. We back companies from their inception and strengthen teams with commercial and scientific expertise. Base Genomics’ success is a perfect example of our model working at its best. This is one of the largest diagnostic deals in UK history and will position Oxford as a centre for early stage cancer detection. OSI will reinvest the proceeds back into the Oxford ecosystem, creating more companies capable of tackling more of the world’s toughest problems,” Alexis Dormandy, OSI Chief Executive Officer.